Zika Virus Testing Market
Report ID: SQMIG35J2478
Report ID: SQMIG35J2478
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2478 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
117
|Figures:
72
Global Zika Virus Testing Market size was valued at USD 284.5 Million in 2024 and is poised to grow from USD 301.91 Million in 2025 to USD 485.4 Million by 2033, growing at a CAGR of 6.12% during the forecast period (2026-2033).
The requirement for rapid diagnostics to prevent neurological and congenital damage in the region with Aedes mosquito transmission is the key factor driving the Zika Virus Testing Market. The market consists of molecular assays, serology and point of care instruments, used by public health authorities, hospitals and prenatal services and it matters because early detection drives targeted vector control, travel advisories, pregnancy counseling and surveillance worldwide. The sector transitioned from fragmented research assays to scalable commercial kits after the 2015 to 2016 Americas epidemic, when global demand for RT PCR and IgM tests surged and investment poured into multiplex panels and portable molecular platforms.
The combination of expanded surveillance needs and maturation is a key driver for market growth as scalable assays enable screening in maternal health, blood banking and outbreak response. For example, during outbreaks, public health agencies in Brazil increased prenatal screening, increasing demand for rapid RT PCR and POC tests, driving manufacturers to optimize isothermal platforms and multiplex panels that can distinguish Zika from dengue and chikungunya. This cascade gave rise to opportunities for repurposing COVID 19 molecular infrastructure, fostering public private partnerships, and opening markets in Southeast Asia and Africa where urbanization and travel patterns increase Aedes exposure, thereby sustaining demand.
How is AI improving diagnostic accuracy in the Zika virus testing market?
AI is mixing machine learning with traditional lab techniques. The Zika virus testing market is a lucrative one. The major improvements are better extraction of signals from molecular assays, and more intelligent interpretation of antibody patterns to reduce cross reacting results with other related flavivirus. Such differences in laboratory workflow and test performance may delay diagnosis. AI tools can help standardize the calling of curves, flag ambiguous results that may need confirmation testing and provide clinical context to make reports clearer. These capabilities accelerate laboratory quality assurance, allowing clinicians to have confidence in the results more quickly, which is critical for outbreak response and routine surveillance.
Diagnostics.ai is a transparent AI PCR platform certified CE IVDR in May 2025, with auditable and explainable decision paths for each test. This new development will help grow the market by making the result clearer and AI guided, increasing reproducibility, lab confidence and reducing repeat testing.
Market snapshot - (2026-2033)
Global Market Size
USD 284.5 Million
Largest Segment
Serological (IgM/IgG) Tests
Fastest Growth
RT-PCR Tests
Growth Rate
6.12% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global zika virus testing market is segmented by test type, sample type, end-user, distribution and region. Based on test type, the market is segmented into RT-PCR Tests, Serological (IgM/IgG) Tests and Rapid Antigen Tests. Based on sample type, the market is segmented into Serum/Blood, Urine and Saliva. Based on end-user, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories and Public Health Labs. Based on distribution, the market is segmented into Direct Sales, Distributors and Government Procurement. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
RT-PCR Tests segment dominates as the most dependable detection during the acute viremic phase, providing the high analytical sensitivity and specificity that clinicians and laboratories trust for confirmatory diagnosis. Institutional adoption and procurement decisions and integration into surveillance programs are driven by compatibility with existing molecular platforms and established laboratory workflows, motivating continued investment in molecular testing capacity and supporting broad clinical and public health use.
However, Serological (IgM/IgG) Tests are the fastest growing segment due to increasing demand for retrospective diagnosis, ease of sample collection in non-acute cases and innovation in assay specificity and automation. Regulatory support for serology validation and expanded use in prenatal screening and epidemiologic studies are driving adoption and creating new diagnostic and public health opportunities.
The urine segment is the most prevalent one owing to the ease of collection, non-invasive approach and the long detection window for viral RNA, which is of great importance in clinical diagnosis and surveillance. This easier sample collection relieves discomfort for patients and allows for testing of pregnant women and children. Lower biosafety and phlebotomy resource logistics requirements make it easier for outpatient clinics and laboratories to adopt and enable stronger community-based screening and outbreak monitoring.
But saliva is the fastest growing sample type as it is non-invasively self-collected, is compatible with point-of-care and rapid assay formats and provides access beyond the hospital setting. Validation studies are ongoing, logistics are being worked out for large-scale screening, and the need for decentralized testing in prenatal and community settings is increasing. This is spurring innovation and creating new testing channels.
To get detailed segments analysis, Request a Free Sample Report
North America is expected to lead the global Zika virus testing market, followed by Europe and Asia. North American Zika virus testing market is majorly driven by the presence of a robust diagnostic ecosystem which comprises of strong laboratory infrastructure, significant public health spending and close collaboration between clinical laboratories and research institutions. Regulatory frameworks that support assay validation and timely adoption drive innovation, and distribution and scale up are supported by established supply chains and experienced manufacturers. Routine testing is supported in care settings of high clinical suspicion with integrated surveillance pathways in place. This will also permit the private sector to participate in the commercialization of new platforms and translational research as well as in the public programs. In addition, collaborations with academic centers and clinical trial activity generate evidence for assay performance, and engagement with payers allows for broader adoption across patient populations. There are other reasons why North America has a strong market presence, too.
Zika Virus Testing Market Extensive laboratory capacity, integrated public health surveillance and a competitive diagnostics industry that prioritizes assay innovation are driving Zika testing in the United States. Clinical networks and academic collaborations allow for strong validation and real world evidence generation, and established distribution channels allow for rapid deployment of diagnostic platforms. Policy frameworks and stakeholder alignment allow for technologies to enter the market and for testing to be embedded across care pathways in practice.
Zika Virus Testing Market in Canada The testing environment in Canada is characterized by collaborative provincial laboratory networks, targeted public health programs, and partnerships that support the delivery of diagnostics to remote settings. Assays need to be reliable across laboratories and this requires investment in training the workforce and quality assurance, and procurement strategies and collaborative purchasing can help provide market certainty for suppliers. Engagement with the clinical setting and integration of surveillance helps to ensure consistent testing practice for early identification and management of cases, and strengthens system resilience.
The acceleration of Europe’s growth depends on the strengthening of cross-border surveillance, harmonized regulatory dialogues and coordinated research networks to speed up assay validation and market access. The diversification of testing modalities and decentralized deployment is supported by a strong base of diagnostic manufacturers and increasing clinical awareness. Investments in lab upgrades and staff training, joint purchasing and payer engagement can help to increase capacity at centralized reference centres and community labs, improving access to advanced diagnostics. Uptake is also supported by public health activities promoting the integration of testing into maternal and travel health programs. Regional centres of excellence foster the creation of evidence for new platforms and the transfer of knowledge to smaller markets, thus improving overall preparedness and diagnostic equity between countries.
Zika Virus Testing Market Germany has a strong base of diagnostics manufacturers, high laboratory standards, and structured public health systems that support assay evaluation and uptake. Strong collaboration between industry, academic centers and federal reference laboratories leads to rigorous performance assessment and clinical validation. Quality and interoperability are stressed in procurement practices to allow integration of different diagnostic platforms. Targeted investment in laboratory modernisation ensures capacity consistency across regional networks and cross border coordination.
United Kingdom Zika Virus Testing Market is experiencing growth due to the innovation ecosystem, regulatory engagement and clinical research requiring new assays. Decentralised laboratory networks and strong primary care pathways increase access to testing. Public health focus on integration of surveillance and maternal screening encourages a variety of diagnostic modalities. Partnerships with industry and academic centers with specialized laboratories allow rigorous validation studies and translation of novel platforms to clinical practice across healthcare settings.
The Zika Virus Testing Market France is driven by targeted investment in laboratory networks, improved surveillance programs and integration of diagnostics into maternal health services. We work with public health agencies, regional laboratories and industry innovators to validate and deploy assays in-house. Higher awareness on quality assurance and laboratory accreditation leads to higher confidence in the results of the tests. Regional policy can mean more consistent approaches and better access across the clinical setting.
The Asia Pacific is improving its market position through laboratory modernization, greater collaboration between public health agencies and private diagnostics companies and targeted capacity building in clinical and reference laboratories. Broader technical expertise and utilization of molecular and serological platforms facilitate more diverse testing portfolios. Standardised training and harmonization of methods through regional centers of excellence. Urban and remote locations can now receive assays due to improvements in procurement and supply chain networks. Cross-border research collaborations and international validation efforts boost the local credibility of new tests. Localized manufacturing partnerships and technical transfer programs accelerate access to affordable diagnostics while supporting long-term sustainability, enhancing regional resilience and market development.
Zika Virus Testing Market Japan is advancing through strong domestic diagnostics innovation, investment in advanced laboratory platforms and close collaboration between specialized research institutes and clinical laboratories. Method validation and clinical adoption are facilitated by regulatory engagement and well-established distribution networks provide reliable access to assays. Quality assurance and laboratory accreditation focus improves confidence in results, and industry academic partnerships drive ongoing assay performance improvement and integration into healthcare workflows.
Zika Virus Testing Market South Korea focuses on adoption of molecular diagnostics, robust manufacturing capacity, and laboratory systems that facilitate dissemination of assays. The industry collaboration with universities and national reference laboratories allows the validation and technology improvement. Procurement & logistics are optimized to improve availability of testing across clinical settings. Workforce training and quality management are the foundation of laboratory readiness; and engagement with industry fosters innovation that more broadly addresses clinical and surveillance needs.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increased Awareness and Surveillance Efforts
Advancements In Molecular Diagnostic Technologies
Regulatory Approval and Validation Challenges
Cross Reactivity and Diagnostic Specificity Issues
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape for global Zika virus testing is increasing the competition among diagnostics firms owing to the demand for multiplex arbovirus assays, blood screening needs and regulatory clearances. Companies such as Beroni with its Columbia license, Roche with its cobas Zika launch, and InBios with its FDA market authorization are pursuing licensing and platform commercialization efforts. Public health collaborations and BARDA contracts help to accelerate deployment and scale.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global Zika virus testing market is propelled primarily by the need for rapid diagnostics to prevent neurological and congenital harm, with a key driver being expanded surveillance and prenatal screening that increase demand for RT-PCR and serology. One restraint is regulatory approval and validation challenges that slow market entry for novel assays. The dominating region is North America thanks to its mature diagnostic ecosystem and public health investment, and the dominating segment is RT-PCR tests due to high analytical sensitivity in acute infection. A second driver is advancements in molecular diagnostic technologies and decentralized point of care platforms that enable faster, multiplexed and field-deployable testing.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 284.5 Million |
| Market size value in 2033 | USD 485.4 Million |
| Growth Rate | 6.12% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Zika Virus Testing Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Zika Virus Testing Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Zika Virus Testing Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Zika Virus Testing Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Zika Virus Testing Market size was valued at USD 284.5 Million in 2024 and is poised to grow from USD 301.91 Million in 2025 to USD 485.4 Million by 2033, growing at a CAGR of 6.12% during the forecast period (2026-2033).
Competitive landscape for global Zika virus testing is driven by regulatory clearances, blood screening needs and demand for multiplex arbovirus assays, intensifying competition among diagnostics firms. Companies pursue licensing and platform commercialization such as Beroni's Columbia license, Roche's cobas Zika launch and InBios' FDA market authorization, while public health collaborations and BARDA contracts accelerate deployment and scale. 'Roche Diagnostics', 'Abbott Laboratories', 'bioMérieux SA', 'Quest Diagnostics', 'Labcorp', 'Altona Diagnostics', 'ELITechGroup', 'InBios International', 'Vela Diagnostics', 'Chembio Diagnostics', 'Creative Diagnostics', 'Eurofins Scientific', 'Focus Diagnostics (DiaSorin)', 'Certest Biotec', 'Molbio Diagnostics'
Increased public and clinical awareness of Zika risk, combined with strengthened surveillance systems, drives greater demand for diagnostic testing by prompting healthcare providers and public health agencies to prioritize screening and confirmatory assays. Enhanced case detection efforts lead institutions to invest in laboratory capacity and procure validated test kits, while surveillance driven testing protocols expand testing volumes and routine use across maternal health and travel clinics. This sustained focus encourages developers to refine assays and supports wider adoption of diagnostic solutions across both centralized and decentralized settings.
Decentralized Point Of Care: Expansion of decentralized point of care testing enables rapid screening in community clinics and rural settings, reducing dependence on centralized laboratories. Easier sample collection workflows and simplified, robust assay formats support deployment by local health workers. This trend drives partnerships with primary care providers and NGOs to increase access during outbreak responses and prenatal screening programs. Manufacturing focus on compact, user-friendly devices encourages scalability and faster adoption, while training and quality programs maintain reliability in varied resource environments and continuity.
Why does North America Dominate the Global Zika Virus Testing Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
